Newsroom

Événements

MSF International Scientific Days are back online from May 10-12, 2022!

The International Scientific Days are THE annual event dedicated to innovation and research in MSF programs worldwide.

Read more

Headline

MSF Foundation in Video

  • WPC Dubai 2023 fondation msf
    Vidéos

    The MSF Foundation 3D program at the WPC World Physiotherapy Congress in Dubai

  • UneEN-Sica
    Vidéos

    Antibiogo : Routine implementation within the MSF Sica Laboratory in Bagui, CAR

News

  • Articles

    Cervical cancer : when AI helps improve diagnosis

    Cervical cancer is the second deadliest cancer in low- and middle-income countries (1). In Malawi in East Africa, where MSF operates, over 4,000 Malawian women fall sick with cervical cancer every year. With 2,905 deaths due to cervical cancer in 2020, the country also had the second highest rate of mortality (2). How can we explain such a high mortality rate from this disease which, in high-income countries, is easily preventable and generally less deadly?  The reasons include limited access to prevention and screening, and diagnoses that are not always reliable.

     

    Clara Nordon, Director of the MSF Foundation, has just got back from a visit to Malawi with the MSF teams and tells us about the project led by the Foundation. Code name: AI4CC

    Read more
  • Utilisation d'Antibiogo au laboratoire MSF, hôpital CHK.Kinshasa. République Démocratique du Congo
    Articles

    Antibiogo is already implemented in routine in DRC and Jordan, and soon within other MSF’s Labs !

    Read more

Publications

  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more

Press Review

No news for now.